The Challenge
Ensuring API emissions from manufacturing are kept below levels that negatively impact human health or the environment
The World Health Organization names antimicrobial resistance (AMR) a top global public health threat. It causes over 1 million deaths a year and, without action, almost 40 million by 2050.
If not properly controlled, waste from antibiotic manufacturing can enter the environment, for example through wastewater, and contribute to AMR, reducing how well antibiotics treat infections. GSK already had a formalized programme to minimize AMR risk across its internal and manufacturing supply chains. Kitemark certification takes this further, independently verifying GSK’s responsible manufacturing practices and commitment to protecting public health and the environment.
The Solution
Demonstrating transparency, accountability and a commitment to addressing the global challenge of AMR
GSK set out to enhance its existing AMR programme and documentation procedures to gain the BSI Kitemark for Minimized Risk of Antimicrobial Resistance at every antibiotic site.
In 2024, GSK’s Worthing site became the first in the UK to achieve the Kitemark, following BSI audits of seven antibiotic products, wastewater treatment operations and storage areas. Certification involves an independent initial assessment followed by annual surveillance. With the certification of its final site in November 2026, GSK became the first pharmaceutical company to certify all of its antibiotic manufacturing sites worldwide, meeting its target for every site to be certified by the end of 2026.